Dyadic International, Inc. (DYAI) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Dyadic International, Inc. (DYAI) closed at USD 0.41 on 2026-10-14, a change of -63.7 % over the past year, with a market capitalization of USD 16.8M.
Dyadic International, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 0.41 |
| 2026-10-13 | 0.43 |
| 2026-10-12 | 0.42 |
| 2026-10-09 | 0.44 |
| 2026-10-08 | 0.44 |
| 2026-10-07 | 0.46 |
| 2026-10-06 | 0.45 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Dyadic International, Inc. key figures
- Previous close
- USD 0.41 (2026-10-14)
- 1-year change
- -63.7 %
- Market cap
- USD 16.8M
- Enterprise value
- USD 17.21M
- P/E ratio (trailing)
- -1.82
- P/E ratio (forward)
- -1.31
- EPS (trailing)
- -0.23
- EPS (forward)
- -0.32
- PEG ratio
- n/a
- Price to book
- -6.35
- Revenue growth
- -0.6 %
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 0.81
- Employees
- 5
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Dyadic International, Inc.
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Dyadic International, Inc. and compare it with other stocks.
Analyze DYAIAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Dyadic International, Inc. shares.